BioSpace News Archive

BD, a leading global medical technology company, announced an agreement with ImageMover, a software platform that automates and simplifies medical data collection and management, to offer a companion mobile app that enables more streamlined reporting of SARS-CoV-2 antigen testing results performed on the BD Veritor™ Plus System at everyday testing locations, such as schools and businesses.

Alphamab Oncology (stock code: 9966.HK) announced that U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug application (IND) to initiate an open label, multi-center phase II pivotal clinical study (clinical trial No.: KN046-205) in the United States to evaluate the efficacy

The peer-reviewed article published in Cancer Discovery, a journal of the American Association for Cancer Research Anat Cohen-Dayag, Ph.D., President and CEO of Compugen: Our discovery of PVRIG as a distinct pathway in the DNAM axis has evolved into a deep and broad understanding of this potentially foundational axis in cancer immunotherapy [09-March-2021]

OncoSynergy, Inc., a physician-founded oncology company committed to advancing therapeutics to address dire unmet medical needs, announced that the first patient was treated in the Company’s First-in-Human Phase 1 clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida.

Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of Jason Campagna , M.D., Ph.D. as Chief Medical Officer. Dr. Campagna brings more than 15 years of biotech and pharmaceutical experience to the Q32 Bio executive team

Acquisition expands Takeda’s immuno-oncology portfolio with two development candidates and Maverick’s conditionally active bispecific T-cell engagers COBRA™ platform, specifically designed to target solid tumors Maverick’s lead candidate TAK-186 (formerly MVC-101), a conditionally active T-cell engager, is first in its class to enter the clinic with recent Phase 1/2 study initiation

Intersect ENT, Inc., a global ear, nose and throat medical technology leader dedicated to transforming patient care, reported financial results for the fourth quarter and full year ended December 31, 2020.

Company presentation features neuro-oncology program with goal of becoming standard of care for diagnosis, characterization and monitoring of metastatic spread of solid tumors to the central nervous system (CNS) Provides update on COVID-19 testing with more than 300,000 samples received

Taysha to have an exclusive option on new payloads, constructs, and intellectual property arising from research conducted under the agreement Agreement leverages Taysha’s existing partnership with UT Southwestern Gene Therapy Program to develop new constructs incorporating novel mini-gene payloads

Sotera Health Company, a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced financial results for the fourth-quarter and full-year 2020.